Home /Research /A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
OTHER

A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer

Erdem Bangi, Celina Ang, Peter Smibert, Andrew Uzilov, Alexander Teague, Yevgeniy Antipin, Rong Chen, Chana Hecht, Nelson Gruszczynski, Wesley J. Yon, Denis Malyshev, Denise Laspina, Isaiah Selkridge, Aye S. Moe, Chun Yee Lau, Patricia Taik, Eric Wilck, Aarti Sonia Bhardwaj, Max W. Sung, Sara Kim

Year
2019
Citations
107
Access
Open access

Abstract

hindgut was developed; a robotics-based screen using this platform identified trametinib plus zoledronate as a candidate treatment combination. Treating the patient led to a significant response: Target and nontarget lesions displayed a strong partial response and remained stable for 11 months. By addressing a disease's genomic complexity, this personalized approach may provide an alternative treatment option for recalcitrant disease such as KRAS-mutant colorectal cancer.

Keywords

TrametinibKRASColorectal cancerMutantMedicineCancerOncologyCancer researchMutationInternal medicine

Related papers

Browse all OTHER papers